

Common variants in *TMPRSS6* are associated with iron status and erythrocyte volume

Beben Benyamin¹, Manuel A R Ferreira¹, Gonneke Willemsen², Scott Gordon¹, Rita P S Middelberg¹, Brian P McEvoy¹, Jouke-Jan Hottenga², Anjali K Henders¹, Megan J Campbell¹, Leanne Wallace¹, Ian H Frazer³, Andrew C Heath⁴, Eco J C de Geus², Dale R Nyholt¹, Peter M Visscher¹, Brenda W Penninx⁵, Dorret I Boomsma², Nicholas G Martin¹, Grant W Montgomery¹ & John B Whitfield¹

We report a genome-wide association study to iron status. We identify an association of SNPs in *TMPRSS6* to serum iron (rs855791, combined $P = 1.5 \times 10^{-20}$), transferrin saturation (combined $P = 2.2 \times 10^{-23}$) and erythrocyte mean cell volume (MCV, combined $P = 1.1 \times 10^{-10}$). We also find suggestive evidence of association with blood hemoglobin levels (combined $P = 5.3 \times 10^{-7}$). These findings demonstrate the involvement of *TMPRSS6* in control of iron homeostasis and in normal erythropoiesis.

Mutations in genes encoding components of iron homeostasis mechanisms can cause overload in hereditary hemochromatosis (commonly associated with *HFE*, but also with *HFE2* (also called *HJV*), *HAMP*, *TFR2* and *SLC40A1*) or deficiency in iron-refractory iron-deficiency anemia (associated with *TMPRSS6*). Although most attention has been paid to variants with major effects leading to inherited disease, variation in iron status within the general population^{1,2} is important in relation to risk of iron-deficiency anemia, oxidative stress, liver disease and metabolic syndrome.

Investigation of iron status in humans can be based on quantitative tests including those for serum iron, serum transferrin, transferrin saturation with iron, and serum ferritin. We aimed to identify polymorphisms causing variation in iron status in the general population using genome-wide association methods in 2,516 adolescent and 2,302 adult individuals from 2,277 Australian twin families (Supplementary Table 1). The genotyping was performed using Human610-Quadv1 chips (~582,000 SNPs) and HumanCNV370-Quadv3 chips (~351,000 SNPs) (Supplementary Methods). We replicated previously reported associations of serum SNPs in *TF* (rs3811647) with serum transferrin and in *HFE* (rs1800562) with

serum iron, transferrin and transferrin saturation² in both the adolescent and adult samples (Table 1, Supplementary Figs. 1 and 2).

We identified significant associations between SNPs in *TMPRSS6* and serum iron (adolescents $P = 1.6 \times 10^{-11}$, adults $P = 9.9 \times 10^{-11}$) and transferrin saturation (adolescents $P = 9.7 \times 10^{-13}$, adults $P = 1.8 \times 10^{-11}$) (Table 1). The strongest *TMPRSS6* association was with rs855791, a nonsynonymous coding SNP (resulting in an A736V substitution) in exon 17 (Fig. 1). The effects of rs855791 on serum iron and transferrin saturation were additive, with each T allele decreasing serum iron and transferrin saturation by 0.18 and 0.20 s.d., respectively, of the values associated with the mean phenotypes. The SNP explains 2.2% and 2.5% of the variation in the means of serum iron and transferrin saturation, respectively, in the adolescent cohort and 1.9% and 2.0% in the adult cohort.

Because of the involvement of *TMPRSS6* mutations in iron-refractory iron-deficiency anemia³ and because low values for blood hemoglobin (Hb) and erythrocyte mean cell volume (MCV) occur in iron-deficiency states, we next checked for associations with Hb or MCV. We found strong associations of rs855791 to Hb ($P = 2.3 \times 10^{-6}$) and MCV ($P = 1.3 \times 10^{-5}$) in the adolescents. The T allele of rs855791 decreased mean Hb and MCV by 0.15 and 0.14 s.d., respectively. These correspond to 1.1% and 0.9% of the total variance in mean Hb and MCV. We replicated these associations in an independent adult Dutch cohort⁴ consisting of 3,470 unrelated individuals ($P = 7.7 \times 10^{-3}$ and 1.8×10^{-6} for Hb and MCV, respectively) (Table 1).

Genotypic means for each of the marker phenotypes for the most significant SNPs in *TF*, *HFE* and *TMPRSS6*, by sex and study cohort, are presented in Supplementary Figure 3a,b. The direction of the allelic effects was consistent with expectation, in that the alleles or genotypes causing low iron or transferrin saturation were the same in the adults and adolescents and were also those associated with lower Hb and MCV. The estimated effect sizes, stratified by gender after correcting for the effect of age, are presented in Supplementary Table 2. Except for the effect of rs1800562 on Hb in the adult cohort, there appear to be no significant differences between the estimates for males and females.

To assess whether the effects of rs855791 on Hb and MCV are explained by effects on iron status, or whether there may be direct effects of *HFE* or *TMPRSS6* variants on erythropoiesis, we repeated the SNP association analysis for Hb and MCV in the Australian adolescents using the residuals after adjustment for the effect of transferrin saturation (chosen because this measure shows the strongest association with rs855791). This first required assessment of the relationships between transferrin saturation, Hb and MCV (Supplementary Fig. 4); these relationships were essentially linear across the range found in this population sample. Results showed that linear adjustment for

¹Queensland Institute of Medical Research, Brisbane, Queensland, Australia. ²Netherlands Twin Register, Department of Biological Psychology, VU University Amsterdam, Amsterdam, The Netherlands. ³Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland, Australia. ⁴Department of Psychiatry, Washington University School of Medicine and Midwest Alcoholism Research Center, St. Louis, Missouri, USA. ⁵Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands. Correspondence should be addressed to B.B. (bebenB@qimr.edu.au).

Received 20 May; accepted 3 August; published online 11 October 2009; doi:10.1038/ng.456

Table 1 Additive effects (in s.d. units) of the three SNPs in *TMPRSS6*, *HFE* and *TF* on iron status

Trait	Adolescent					Adult					Combined		
	N	Beta	s.e.	R ² (%)	P	N	Beta	s.e.	R ² (%)	P	Beta	s.e.	P
rs855791 (<i>TMPRSS6</i>)													
Iron	2,505	-0.183	0.027	2.2	1.6 × 10 ⁻¹¹	2,298	-0.191	0.030	1.9	9.9 × 10 ⁻¹¹	-0.187	0.020	1.5 × 10 ⁻²⁰
Transferrin	2,513	0.078	0.029	0.4	7.1 × 10 ⁻³	2,299	0.069	0.031	0.2	0.023	0.074	0.021	4.9 × 10 ⁻⁴
Saturation	2,503	-0.196	0.027	2.5	9.7 × 10 ⁻¹³	2,294	-0.198	0.029	2.0	1.8 × 10 ⁻¹¹	-0.197	0.020	2.2 × 10 ⁻²³
Log ₁₀ (ferritin)	2,512	-0.092	0.028	0.5	8.8 × 10 ⁻⁴	2,301	-0.040	0.030	0.1	0.17	-0.068	0.021	9.3 × 10 ⁻⁴
Hb	2,468	-0.151	0.032	1.1	2.3 × 10 ⁻⁶	3,188	-0.067	0.025	0.2	7.7 × 10 ⁻³	-0.099	0.020	5.3 × 10 ⁻⁷
MCV	2,467	-0.139	0.032	0.9	1.3 × 10 ⁻⁵	3,181	-0.120	0.025	0.7	1.8 × 10 ⁻⁶	-0.127	0.020	1.1 × 10 ⁻¹⁰
rs1800562 (<i>HFE</i>)													
Iron	2,502	0.343	0.052	2.2	4.7 × 10 ⁻¹¹	2,299	0.315	0.053	1.5	2.5 × 10 ⁻⁹	0.329	0.037	8.2 × 10 ⁻¹⁹
Transferrin	2,510	-0.602	0.056	6.0	4.3 × 10 ⁻²⁷	2,300	-0.605	0.055	5.4	2.9 × 10 ⁻²⁸	-0.604	0.039	2.2 × 10 ⁻⁵³
Saturation	2,500	0.598	0.053	6.6	2.3 × 10 ⁻²⁹	2,295	0.523	0.054	4.2	3.0 × 10 ⁻²²	0.561	0.038	8.5 × 10 ⁻⁵⁰
Log ₁₀ (ferritin)	2,509	0.168	0.053	0.5	1.6 × 10 ⁻³	2,302	0.103	0.054	0.2	0.06	0.136	0.038	3.4 × 10 ⁻⁴
Hb	2,465	0.236	0.061	0.8	1.2 × 10 ⁻⁴	3,451	0.169	0.051	0.3	9.0 × 10 ⁻⁴	0.197	0.039	5.1 × 10 ⁻⁷
MCV	2,464	0.148	0.061	0.3	0.015	3,442	0.273	0.051	0.8	7.7 × 10 ⁻⁸	0.222	0.039	1.5 × 10 ⁻⁸
rs3811647 (<i>TF</i>)													
Iron	2,505	0.073	0.029	0.3	0.012	2,299	0.042	0.032	0.1	0.18	0.059	0.022	0.006
Transferrin	2,513	0.460	0.031	11.2	4.4 × 10 ⁻⁵⁰	2,300	0.371	0.032	6.1	2.1 × 10 ⁻³⁰	0.417	0.022	2.1 × 10 ⁻⁷⁸
Saturation	2,503	-0.089	0.029	0.5	2.4 × 10 ⁻³	2,295	-0.093	0.031	0.4	3.1 × 10 ⁻³	-0.091	0.021	1.8 × 10 ⁻⁵
Log ₁₀ (ferritin)	2,512	-0.053	0.029	0.2	0.07	2,302	-0.030	0.032	0.1	0.35	-0.044	0.022	0.04
Hb	2,468	-0.019	0.034	0.02	0.58	3,470	0.032	0.026	0.04	0.21	0.013	0.021	0.52
MCV	2,467	-0.041	0.034	0.1	0.23	3,461	-0.042	0.026	0.1	0.10	-0.042	0.021	0.04

Iron status parameters tested were serum iron, serum transferrin, transferrin saturation, serum ferritin and blood hemoglobin (Hb) levels and erythrocyte mean cell volume (MCV). The results are from the Australian cohorts, except for Hb and MCV in adults, which are from the Dutch cohort. The results in the adolescent cohort are from the mean of measurements from up to four visits. The rs855791 variant was not genotyped in the Dutch panel and so was imputed using PLINK¹¹ as described previously¹². Genotypes were imputed with high confidence (information score of 0.97) in 92% of individuals. Minor allele frequencies (MAFs) for rs855791 (T), rs1800562 (A) and rs3811647 (A) in the adolescent cohort are 0.42, 0.08 and 0.33, respectively. R² is the proportion of the phenotypic variance explained by each SNP. After correction for multiple testing, there is no significant evidence for heterogeneity between the effect sizes in adolescent and adult data.

transferrin saturation reduced but did not eliminate the effects of rs855791 in *TMPRSS6* on Hb (from R² = 1.2%, P = 1.4 × 10⁻⁶, to R² = 0.5%, P = 0.003), and MCV (from R² = 0.8%, P = 6.9 × 10⁻⁵, to R² = 0.4%, P = 0.008). Similar adjustment essentially eliminated the effects of rs1800562 in *HFE* (for Hb, from R² = 0.8%, P = 1.1 × 10⁻⁴, to R² = 0.2%, P = 0.09; for MCV, from R² = 0.4%, P = 0.007, to R² < 0.1%, P = 0.40). The residual allelic association with rs855791, together with the strong overall association between transferrin saturation and Hb or MCV (Supplementary Table 3 and Supplementary Fig. 4), suggest that the effects of this *TMPRSS6* polymorphism on Hb and MCV may not be solely due to the availability of transferrin-bound iron being rate-limiting for erythropoiesis.

We have shown genome-wide significant association of a common SNP in *TMPRSS6* with serum iron, transferrin saturation and MCV, and suggestive association with Hb,

extending previous data² implicating *TMPRSS6* in variation in serum iron and transferrin saturation in the general population. Data from other sources^{3,5-7} shows that knockout (in mice) or mutations with major effect (in humans) in *TMPRSS6* greatly affect iron status. Loss




Figure 1 Detailed results of the associations between SNPs within *TMPRSS6* and transferrin saturation in the adolescent cohort. (a) The genomic location of *TMPRSS6* at 22q12-q13 on chromosome 22. (b) $-\log_{10}(P)$ of the association tests between SNPs and transferrin saturation, where red dots indicate genome-wide significant SNPs. rs2160906 has a significant *cis*-acting effect on *TMPRSS6* expression ($P = 8.4 \times 10^{-8}$)¹⁰. (c) Linkage disequilibrium (LD) (r^2) between rs855791 and all other HapMap SNPs within *TMPRSS6*. (d) HapMap-LD plot (r^2) between genotyped SNPs within *TMPRSS6*.

of function in this gene produces iron deficiency and anemia, probably through a combination of protease action on hemojuvelin⁶ and regulation of the expression of hepcidin⁸. We have now found significant and consistent effects of a *TMPRSS6* variant on both iron status (serum iron and transferrin saturation) and erythropoiesis (Hb and MCV) in adolescents and adults from the general population. The effects of this nonsynonymous coding variant on both Hb and MCV raise important questions about the relationship between iron status and normal Hb synthesis. One implication is that transferrin saturation may be involved in the control of erythropoiesis and that alleles which increase it allow an increase in Hb and MCV even in people who show no evidence of iron deficiency.

There are now confirmed effects on iron markers for three genes, each previously known from human case studies or mouse experiments to affect iron homeostasis. *TF* mainly affects the concentration of its protein product transferrin, and this may in turn affect the concentration of diferric transferrin, which regulates hepcidin expression in the liver by interacting with the *HFE* and *TFR2* gene products⁹. *HFE* likewise regulates hepcidin, and naturally occurring or experimentally induced mutations in this gene lead to iron overload. In our study, the associations of *HFE* to serum iron, serum transferrin and transferrin saturation, but not to serum ferritin, met genome-wide significance in these cohorts. With the sample size of the cohorts included in this study, we do not have power to detect any ferritin-associated SNPs at genome-wide significance levels. Note that rs855791 and rs1800562 were associated with serum ferritin, with combined *P* values around 10^{-4} (Table 1).

Loss-of-function mutations affecting the protease domain of the *TMPRSS6* gene product, matriptase-2 (also called transmembrane protease, serine 6), lead to increased hepcidin expression and iron deficiency⁵⁻⁷. The variant that has the largest effect in this study produces an amino acid change, from alanine to valine at amino acid 736. This, too, is in the protease domain, and we speculate that it may lead to changes in protease activity. Other variants of *TMPRSS6* may also affect iron status. A report on gene expression in human liver¹⁰ found a *cis*-acting effect of rs2160906 ($P = 8.4 \times 10^{-8}$, HapMap CEU r^2 with rs855791 = 0.06) at 35.82 Mb on *TMPRSS6* expression, and we found strong supportive evidence (combined $P = 9.8 \times 10^{-8}$ with transferrin saturation) for an effect of this polymorphism on iron status (Fig. 1).

Heritability estimates¹ suggest that there must be other genetic contributions to variation in these traits, but their identification will require larger studies or meta-analysis of multiple studies. Polygenic effects on iron status may have clinical importance for iron overload states, both primary (as risk modifiers in *HFE* C282Y homozygotes) and secondary to liver disease or metabolic syndrome, and case-control studies on the effects of *TMPRSS6* variation in these conditions are needed.

Note: Supplementary information is available on the Nature Genetics website.

ACKNOWLEDGMENTS

We are grateful to the twins and their families for their generous participation in these studies. We would like to thank staff at the Queensland Institute of Medical Research: D. Statham, A. Eldridge and M. Grace for the Australian sample collection; L. Bowdler, S. Crooks and staff of the Molecular Epidemiology Laboratory for sample processing and preparation; D. Smyth and H. Beebey for IT support; M. Wright for supervision and A. McRae and S. Medland for discussion. For the Australian study, we acknowledge funding from the Australian National Health and Medical Research Council (NHMRC grants 241944, 389875, 389891, 389892, 389938, 442915, 442981, 496739 and 552485), US National Institutes of Health (NIH grants AA07535, AA10248 and AA014041) and the Australian Research Council (ARC grant DP0770096). For the Netherlands Twin Registry (NTR) and the Netherlands Study of Depression and Anxiety (NESDA) samples, we acknowledge support from The Netherlands Society for Scientific Research (NWO 904-61-090; 904-61-193; 480-04-004; 400-05-717; SPI 56-464-14192), Center for Medical Systems Biology (NWO Genomics); Geestkracht program of ZonMW (10-000-1002); matching funds from universities and mental health care institutes involved in NESDA (GGZ Buitendamstel-Geestgronden, Rivierduinen, University Medical Center Groningen, GGZ Lentis, GGZ Friesland, GGZ Drenthe); Centre for Neurogenomics and Cognitive Research VU University (CNCR-VU); European Science Foundation (EU/QLRT-2001-01254); NIMH (R01 MH059160); and matching funds from participating institutes in NTR and NESDA. Genotyping of NTR and NESDA samples was funded by the Genetic Association Information Network (GAIN) of the Foundation for the US National Institutes of Health, and analysis was supported by grants from GAIN and the National Institute of Mental Health (MH081802). B.B. is the recipient of an NHMRC Biomedical Postdoctoral Fellowship (552498). D.R.N., G.W.M and P.M.V. are supported by the NHMRC Fellowship Scheme.

AUTHOR CONTRIBUTIONS

Study design and coordination: A.C.H., A.K.H., B.W.P., D.I.B., D.R.N., E.J.C.deG., G.W.M., I.H.F., J.B.W., N.G.M. and P.M.V. Obtaining study funding: A.C.H., B.W.P., D.I.B., D.R.N., E.J.C.deG., G.W.M., I.H.F., J.B.W., N.G.M. and P.M.V. Sample collection and phenotype data collection: A.C.H., A.K.H., D.R.N., G.W.M., I.H.F., J.B.W., L.W., M.J.C. and N.G.M. (Australian); B.W.P., D.I.B., E.J.C.deG., G.W. and J.-J.H. (Dutch). Data preparation: A.K.H., B.B., B.P.M., D.R.N., J.B.W., J.-J.H., L.W., M.J.C., R.P.S.M. and S.G. Statistical analyses: B.B., B.P.M., D.R.N., J.B.W., M.A.R.F., P.M.V. and S.G. Results interpretation: B.B., D.R.N., G.W.M., J.B.W., M.A.R.F., N.G.M. and P.M.V. Manuscript writing: B.B., M.A.R.F. and J.B.W. Review and revision of the manuscript: A.C.H., B.B., B.W.P., D.I.B., D.R.N., E.J.C.deG., G.W., G.W.M., J.B.W., M.A.R.F., N.G.M. and P.M.V. All authors contributed to the final version of the paper.

Published online at <http://www.nature.com/naturegenetics/>.

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>.

- Whitfield, J.B. *et al. Am. J. Hum. Genet.* **66**, 1246–1258 (2000).
- Benyamin, B. *et al. Am. J. Hum. Genet.* **84**, 60–65 (2009).
- Finberg, K.E. *et al. Nat. Genet.* **40**, 569–571 (2008).
- Boomsma, D.I. *et al. Eur. J. Hum. Genet.* **16**, 335–342 (2008).
- Melis, M.A. *et al. Haematologica* **93**, 1473–1479 (2008).
- Silvestri, L. *et al. Cell Metab.* **8**, 502–511 (2008).
- Ramsay, A.J., Hooper, J.D., Folgueras, A.R., Velasco, G. & Lopez-Otin, C. *Haematologica* **94**, 840–849 (2009).
- Muckenthaler, M.U. *Cell Metab.* **8**, 1–3 (2008).
- Gao, J. *et al. Cell Metab.* **9**, 217–227 (2009).
- Schadt, E.E. *et al. PLoS Biol.* **6**, e107 (2008).
- Purcell, S. *et al. Am. J. Hum. Genet.* **81**, 559–575 (2007).
- Ferreira, M.A. *et al. Nat. Genet.* **40**, 1056–1058 (2008).